In BRIP1 carriers and mutation-negative, intermediate risk women (5–10% lifetime ovarian cancer risk) with a strong family history, it may be delayed until 45–50 years (Appendix I).29,30 A significant number of women undergoing RRSO will end up with premature iatrogenic menopause (with the average age of natural menopause being 51 years) requiring HRT. The gene discussed is BRIP1; the disease is ovarian cancer.